

Adherium Extraordinary General Meeting

CEO update

July 2020

Disclaimer and Forward Looking Statement

The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or potential opportunities.

This presentation may contain budget information, forecasts and forward looking statements in respect of which there is NO guarantee of future performance and which of themselves involve significant risks (both known and unknown). Actual results and future outcomes will in all likelihood differ from those outlined herein.


Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding market size, future results, regulatory approvals, production targets, sales, staffing levels etc. All of such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

These risks and uncertainties include, but are not limited to: (i) the possible delays in and the outcome of product development, (ii) risks relating to possible partnering or other like arrangements, (iii) the potential for delays in regulatory approvals, (iv) the unknown uptake and market penetration of any potential commercial products and (vi) other risks and uncertainties related to the Company’s prospects, assets / products and business strategy. This is particularly the case with companies such as Adherium which operate in the field of developing and commercializing medical devices and related services. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Additionally there are a number of factors, both specific to Adherium and of a general nature, which may affect the future performance of Adherium. There is no guarantee that Adherium will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realized.

- A leader in digital inhaled device adherence, remote monitoring and data management solutions for asthma and COPD patients
- Adherium develops, manufactures and supplies a broad range of connected sensors for inhaled respiratory medications for patients, healthcare providers, pharmaceutical companies, and contract research organisations.
- Adherium's Hailie® platform is designed to help patients achieve better adherence and improve health economic outcomes for patients, physicians and payors
- Hailie® technology effectiveness has been demonstrated :
 - >85 peer reviewed publications
 - Over 170,000 sensors sold globally
 - ~13,000 patients
 - 30+ countries
 - Patents in place; proprietary algorithms
- Hailie® Sensor portfolio covers 80% of the US market for inhaled asthma and COPD drugs
- Company currently ~ 20 FTEs based in Auckland, Melbourne, UK and North America
- Company founded in 2001. Listed on ASX in 2015

Hailie® Platform is Designed to Capture & Report Data Enabling Physicians to Improve Patient Outcomes



Percentage reduction vs. control group

59%

Missed doses

80%

Hospital admissions

61%

Acute Attacks

39%

Oral Steroid Use






15%

Missed School Days




Vision and Strategy

To be the
preferred respiratory
inhalation monitoring system,
enabling better clinical and
financial outcomes for
physicians, payers and
patients with severe,
uncontrolled asthma
and COPD

Critical success factors in place to secure business traction

- | | | |
|--|---|---|
| Market Environment |  | <ul style="list-style-type: none">• High medical unmet• Compelling economic rationale in severe asthma/COPD patients• Economic incentives for remote monitoring |
| Technology market ready for extensive commercial use |  | <ul style="list-style-type: none">• Extensive market validation across multiple customers, geographies healthcare settings• Bluetooth® synchronisation with set-up and maintenance supported by customer support tools web/call centre |
| Meaningful customer data generation with outcome measures |  | <ul style="list-style-type: none">• Improves patient adherence• Supports healthcare cost savings |
| Digital interface “humanised” with customer interface |  | <ul style="list-style-type: none">• Establish call centre support through partners<ul style="list-style-type: none">– securing adoption & maintenance of patient engagement– facilitating physician interface & reimbursement processing |
| Business model driven by established specialist partners |  | <ul style="list-style-type: none">• Established partners agnostic to therapeutic choices• Recurring revenue generation potential vs. project-based activity |

Significant unmet need and healthcare burden in severe Asthma (25million, US) & COPD (24million, US)



Proportion of
asthmatics with
difficult to treat and
or severe asthma



Over **8m** treated maintenance asthma patients in US demonstrate “uncontrolled symptoms”

Approx. **50%**
patients fail to take dose as prescribed

US economic burden of asthma & COPD
> US\$100bn

Approx. **US\$4bn**
estimated as preventable healthcare cost for uncontrolled patients

Over **1.3m** severe treated asthma & COPD patients in US

Severe treated patient cost
> US\$10,000 per annum


Graphic adapted from © Global Initiative for Asthma, www.ginasthma.org

1. Hekking et al, JACI 2015
These data are from a Dutch population survey of people ≥18 years with asthma

GP OR SPECIALIST CARE



SPECIALIST CARE; SEVERE ASTHMA CLINIC IF AVAILABLE



SPECIALIST AND PRIMARY CARE IN COLLABORATION



An opportunity for Adherium at diagnosis and at the transition to biologicals to optimise medication use, saving healthcare \$\$ with providers reimbursed through payment codes

Business plan generates recurring revenue




Patient physiological data is captured/recorded

Provider bills
CPT Code #99453/4/7
US\$1,400
per patient

Positive Reimbursement Environment

Covid-19: Accelerated Adoption



OPPORTUNITY

Over **8m** treated maintenance asthma patients in US demonstrate “uncontrolled symptoms”

Approx. **50%** patients fail to take dose as prescribed

US economic burden of asthma & COPD > **US\$100bn**

Approx. **US\$34bn** estimated as preventable healthcare cost for uncontrolled patients

Over **1.3m** severe treated asthma & COPD patients in US

Severe patient cost > **US\$10,000** per annum

Positive International Treatment Guidelines



Specialist Partners



adherium

Approved Products & Pipeline

Recurring Revenue



- Per sensor per member per month fee
- Enhanced risk share savings over historic baseline
- Providers to access the CPT fee, with Adherium accessing fee for service
- Sell Adherium devices with a license fee per patient and data access payment

Enhanced Product & Platform Portfolio development

Sensor development partnership programme 2020 - 2021

CURRENT



GSK Ventolin HFA



Teva ProAir HFA



GSK Advair HFA



GSK Flovent HFA



AZ Symbicort



GSK Diskus
Advair/Flovent

RESCUE/RELIEVER

IN DEVELOPMENT



Merck Proventil



BI Respimat Spiriva



BI HandiHaler Spiriva



GSK Ellipta Breo/Trelegy

PREVENTER

SENSOR DEVELOPMENT PIPELINE



Adherium and Planet Innovation teams progress portfolio development

H2 2020

First new sensors with physiological measure launch in US to support CPT code reimbursement

H1 2021

Completion of enhanced sensor portfolio launches in US across Asthma and COPD

H2 2021




hailie®




Sensor attaches to inhaled medication device. Captures medication use and physiological measure data

Patient data reporting

- Monitors device activation, adherence and timing
- Physiological measures in development
- Reimbursement-compliant data
- Patient Feedback via app as appropriate



Payer / Provider Online interfaces




Reimbursement-compliant reports
Billing support Audit trail

Regulatory-compliant cloud infrastructure

Future Data And Freemium Services

Clinician



Tailored Clinical Data reports
Clinical Dashboard
Direct-connect to cloud

SOFTWARE DEVELOPMENT PIPELINE



Increase Platform capacity and capability

H2 2020

*Add new features to app and platform including physiological measures

Enhanced software to improve user experience and flexibility of data integration

H2 2020

1

Q3 2020 – Q1 2021

Initial partner model establishment / proof of concept

- Testing and proving of HGE and Trudell commercial operations and Adherium sensor/software with limited initial sensor volumes and orders
- Appointment of key leadership roles in US and CTO in Australia

2

Q2 2021 – Q4 2021

Partner scale up in US with revenue traction

- Scale up of HGE and Trudell activity with progressive revenue growth alongside introduction of first wave new sensors enabling physiological/peak flow measurement
- Development completion and market launch of full range of physiologically enabled sensor and software in both COPD and Asthma
- Limited highly selective non-US key account management/initial Adherium commercialisation

3

2022

Full expansion and platform leverage in US and ex US

- Accelerated US partners activity with all major new sensors on market
- Potential expanded scale up in EU/ROW territories
- Potential next wave device development including nebulisers/integrated sensors
- Potential multi-provider data integration leverage and monetisation

Investor opportunity for significant value re-rating with business progression

- High level of investor interest in technology and digital funds
- Telehealth/Remote Patient Monitoring acceleration and COVID-19 intensifying investor focus in segment
- Series of successful established and start up medical device businesses adopting digital platforms with Remote Patient Monitoring reimbursement
 - Medtronic
 - Resmed
 - Livongo/Dexcom
 - Senseonics
- Adherium opportunity enhanced with new reimbursement coding and de-risked following key learnings since IPO with qualified experienced management
- Opportunity for organic re-rating alongside strategic M+A as seen with Resmed acquisition of Propeller Health for US\$225m in 2019

Adherium: Compelling Business & Investment Opportunity

- High Unmet Medical Need and Healthcare Resource Burden in Asthma and COPD especially in more severe uncontrolled patient segments
- Global Treatment Guidelines now recommend use of electronic monitoring tools in assessment of severe patient segment prior to changes in medication
- Reimbursement for Remote Patient Monitoring now established in US with adoption of telehealth / remote monitoring accelerating further as a result of COVID-19
- Adherium's clinically supported technology platform with extensive inhaled device coverage
- Adherium strategy, business model, portfolio and new management team in place with key learnings applied since IPO

New Highly Qualified Management in Place



James Ward-Lilley
Chairman

- Extensive experience in operational & executive leadership roles in pharmaceutical & medical devices industry
- >28 years in global roles at **AstraZeneca**, successfully leading their Respiratory & AutoImmune Global Franchise
- Then joined **Vectura PLC**, the inhaled respiratory formulation and device specialists, as Chief Executive
- During time at both **AstraZeneca** and at **Vectura**, worked closely with both **Adherium** & **Propeller Health**



Mike Motion
Chief Executive Officer

- >35 years experience in medical devices & pharmaceuticals
- 15 years **Baxter Healthcare** in manufacturing, sales & marketing & international commercial leadership roles
- Joined **Biocompatible's**, 2005, led commercialisation of its interventional oncology (IO) portfolio, setting up a direct US sales force & global distributor network
- Grew the IO business to ~US\$40m; acquired by **BTG**, 2011 for US\$283m
- Led **BTG Oncology**, Digital & Vein franchises until **BTG** acquired by **Boston Scientific** 2019
- Joined **Adherium**, November 2019: key activities to date include re-financing activity, refresh of strategy, new business model, technology development plan



Anne Bell
Chief Financial Officer

- Qualified as a Chartered Accountant in 1984 with **Arthur Young** before joining **Arthur Andersen** & becoming a partner in the Business Consulting practice
- Joined **Colonial** (subsequently acquired by Commonwealth Bank of Australia) in 1996
- Global roles with **AstraZeneca** 2003-2008
- CFO for **Invida**, which was bought by **Menarini** in 2011 – remained at **Menarini** until 2018



Geoff Feakes
Chief Technical Officer

- >25 years of information technology governance and leadership, solution innovation and realization across Australia and Internationally including Europe, USA and Asia
- Executive positions in the Acute healthcare sector in Australia and 10 years with **Tunstall Healthcare**, both globally and Australasia
- Extensive experience with Remote Patient and Chronic Disease management platforms and solutions, including development and market release
- Board Member and Vice Chair of Australia's Personal Emergency Response Services Limited (PERSL), and committee member of the Medical Technology Association of Australia (MTAA)



Jane Lapon
Head of Pricing & Reimbursement

- >25 years international experience in pricing and reimbursement in medical devices
- Held executive positions with **Bristol-Myers Squibb**, **BTG** and **Boston Scientific**
- Exemplary track record ensuring physicians get paid by public & private payers for company products globally
- Achievements include securing reimbursement for:
 - Failing pulmonology device in Germany, reversing business trajectory
 - Flagship device in France, securing ~€60m/year in public funding, resulting in exponential sales in a previously untapped market

